PBMs’ ‘Perverse Incentives’ Still Limiting Generics Access, AAM Report Reiterates

Supply Chain Middlemen Continue To Block Patient Access To Cheaper Generic Drugs

Generic medicines continue to be intentionally left off formulary tiers in favor of more expensive brand medications, according to a new report from the US Association for Accessible Medicines.

Woman holding up her hand
Many patients are unable to access cheaper generics due to formulary decisions • Source: Shutterstock

The US Association for Accessible Medicines has released a report doubling down on its criticisms of healthcare industry ‘middlemen’, such as health plans and pharmacy benefit managers, for blocking patient access to and delaying coverage of new generic drugs in favor of higher-priced brand drugs with high rebates.

“Patients and the health care system win when new, lower-cost generic drugs enter the market,” said David Gaugh, AAM’s interim CEO. “But too many PBM and health plan formularies are...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

‘Obsessive’ Teva Aims For $800m Biosimilar Sales By 2027

 
• By 

Teva says it is now in the “accelerate growth” phase of its strategic roadmap, with global biosimilar launches set to help the firm achieve its goals.

Trump-Trimmed FDA Finally Releases A Batch Of PSGs – Back To Business As Usual?

 

After half a year of silence, the US FDA has published 48 product-specific guidances for generic development. With critical staff laid off, will the health agency stick to its updated PSG publishing schedule?

Fresenius Adds To Denosumab Competitors In Europe

 
• By 

At a busy meeting of the CHMP, the EMA issued positive opinions for Fresenius Kabi’s denosumab rivals to Prolia and Xgeva, another denosumab biosimilar from Sandoz, a Tecfidera hybrid from Neuraxpharm and a Descovy generic from Viatris. Meanwhile, Ascend has withdrawn a teriparatide filing.

After Dasatinib Apotex Debuts US Tasigna Competition

 
• By 

Canada’s Apotex is continuing to spearhead generic competition in the tyrosine kinase inhibitor (TKI) space for chronic myelogenous leukemia, with the launch of the first generic version of Novartis’ Tasigna (nilotinib) blockbuster.

More from Products

Alvotech And Advanz Add Three More In €160m EU Partnership Expansion

 
• By 

Fresh from filing a proposed biosimilar to Xolair (omalizumab) in the UK, Alvotech and Advanz have shaken hands on a further deal to expand their partnership.

After Dasatinib Apotex Debuts US Tasigna Competition

 
• By 

Canada’s Apotex is continuing to spearhead generic competition in the tyrosine kinase inhibitor (TKI) space for chronic myelogenous leukemia, with the launch of the first generic version of Novartis’ Tasigna (nilotinib) blockbuster.

Abiogen And mAbxience Join Forces In Italy

 
• By 

Spanish biosimilars developer mAbxience has struck a deal with Italy’s Abiogen covering an undisclosed biosimilar for the Italian market.